Oomen Patrick G A, Hakkers Charlotte S, Arends Joop E, van der Berk Guido E L, Pas Pascal, Hoepelman Andy I M, van Welzen Berend J, du Plessis Stefan
Department of Internal Medicine and Infectious Diseases, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
Department of Internal Medicine and Infectious Diseases, Onze Lieve Vrouwe Gasthuis, Oosterpark 9, 1091 AC, Amsterdam, The Netherlands.
Infect Dis Ther. 2024 May;13(5):1067-1082. doi: 10.1007/s40121-024-00966-7. Epub 2024 Apr 20.
It is unclear whether neurotoxicity due to the antiretroviral drug efavirenz (EFV) results in neurocognitive impairment in people living with HIV (PLWH). Previously, we found that discontinuing EFV was associated with improved processing speed and attention on neuropsychological assessment. In this imaging study, we investigate potential neural mechanisms underlying this cognitive improvement using a BOLD fMRI task assessing cortical and subcortical functioning.
Asymptomatic adult PLWH stable on emtricitabine/tenofovirdisoproxil/efavirenz were randomly (1:2) assigned to continue their regimen (n = 12) or to switch to emtricitabine/tenofovirdisoproxil/rilpivirine (n = 28). At baseline and after 12 weeks, both groups performed the Stop-Signal Anticipation Task, which tests reactive and proactive inhibition (indicative of subcortical and cortical functioning, respectively), involving executive functioning, working memory, and attention. Behavior and BOLD fMRI activation levels related to processing speed and attention Z-scores were assessed in 17 pre-defined brain regions.
Both groups had comparable patient and clinical characteristics. Reactive inhibition behavioral responses improved for both groups on week 12, with other responses unchanged. Between-group activation did not differ significantly. For reactive inhibition, positive Pearson coefficients were observed for the change in BOLD fMRI activation levels and change in processing speed and attention Z-scores in all 17 regions in participants switched to emtricitabine/tenofovir disoproxil/rilpivirine, whereas in the control group, negative correlation coefficients were observed in 10/17 and 13/17 regions, respectively. No differential pattern was observed for proactive inhibition.
Potential neural mechanisms underlying cognitive improvement after discontinuing EFV in PLWH were found in subcortical functioning, with our findings suggesting that EFV's effect on attention and processing speed is, at least partially, mediated by reactive inhibition.
Clinicaltrials.gov identifier [NCT02308332].
抗逆转录病毒药物依非韦伦(EFV)所致的神经毒性是否会导致HIV感染者(PLWH)出现神经认知障碍尚不清楚。此前,我们发现停用EFV与神经心理学评估中处理速度和注意力的改善有关。在这项影像学研究中,我们使用一项评估皮层和皮层下功能的BOLD功能磁共振成像任务,调查这种认知改善背后的潜在神经机制。
对接受恩曲他滨/替诺福韦酯/依非韦伦治疗且病情稳定的无症状成年PLWH,按1:2随机分组,分别继续原治疗方案(n = 12)或换用恩曲他滨/替诺福韦酯/利匹韦林(n = 28)。在基线期和12周后,两组均进行停止信号预期任务,该任务测试反应性抑制和主动性抑制(分别指示皮层下和皮层功能),涉及执行功能、工作记忆和注意力。在17个预先定义的脑区评估与处理速度和注意力Z分数相关的行为和BOLD功能磁共振成像激活水平。
两组患者的患者特征和临床特征具有可比性。第12周时两组的反应性抑制行为反应均有所改善,其他反应未变。组间激活无显著差异。对于反应性抑制,换用恩曲他滨/替诺福韦酯/利匹韦林的参与者中,所有17个脑区的BOLD功能磁共振成像激活水平变化与处理速度和注意力Z分数变化之间均观察到正Pearson系数,而在对照组中,分别在10/17和13/17个脑区观察到负相关系数。主动性抑制未观察到差异模式。
在PLWH中停用EFV后认知改善背后的潜在神经机制存在于皮层下功能中,我们的研究结果表明,EFV对注意力和处理速度的影响至少部分是由反应性抑制介导的。
Clinicaltrials.gov标识符 [NCT02308332] 。